TissGeneSummary for TUBA3E |
Gene summary |
Basic gene information | Gene symbol | TUBA3E |
Gene name | tubulin, alpha 3e | |
Synonyms | - | |
Cytomap | UCSC genome browser: 2q21.1 | |
Type of gene | protein-coding | |
RefGenes | NM_207312.2, | |
Description | alpha-tubulin 3Etubulin alpha-3E chain | |
Modification date | 20141207 | |
dbXrefs | HGNC : HGNC | |
Ensembl : ENSG00000152086 | ||
HPRD : 17288 | ||
Vega : OTTHUMG00000131626 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_TUBA3E | |
BioGPS: 112714 | ||
Pathway | NCI Pathway Interaction Database: TUBA3E | |
KEGG: TUBA3E | ||
REACTOME: TUBA3E | ||
Pathway Commons: TUBA3E | ||
Context | iHOP: TUBA3E | |
ligand binding site mutation search in PubMed: TUBA3E | ||
UCL Cancer Institute: TUBA3E | ||
Assigned class in TissGDB* | B | |
Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of TUBA3E | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for TUBA3E |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
KIRC | 0.702450923 | -2.228997688 | 2.931448611 | 1.17E-10 | 4.13E-10 |
BRCA | 1.062386084 | -0.966246372 | 2.028632456 | 7.46E-13 | 3.39E-12 |
Top |
TissGene-miRNA for TUBA3E |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for TUBA3E |
TissGeneSNV for TUBA3E |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.R339H | STAD | 2 |
p.S277X | LIHC | 1 |
p.T109N | LUAD | 1 |
p.G142R | SKCM | 1 |
p.R373Q | PAAD | 1 |
p.R243Q | READ | 1 |
p.N216S | SKCM | 1 |
p.D47N | UCEC | 1 |
p.A333T | STAD | 1 |
p.F267S | STAD | 1 |
p.E22K | SKCM | 1 |
p.T82S | LUAD | 1 |
p.E411K | LUSC | 1 |
p.R123H | UCEC | 1 |
p.E196K | SARC | 1 |
p.W346C | LUAD | 1 |
p.S187F | LUSC | 1 |
p.E297K | SKCM | 1 |
p.R229H | PAAD | 1 |
p.E448X | THYM | 1 |
p.R243Q | UCEC | 1 |
p.E297K | UCS | 1 |
p.P307H | STAD | 1 |
p.E448K | UCEC | 1 |
p.T239R | LUAD | 1 |
p.T361P | LUAD | 1 |
p.A383T | HNSC | 1 |
p.E207Q | BLCA | 1 |
p.T223K | LUAD | 1 |
p.R422C | COAD | 1 |
p.A385V | STAD | 1 |
p.E220* | UCEC | 1 |
p.D205N | BLCA | 1 |
p.G95R | BLCA | 1 |
p.L217M | LUAD | 1 |
p.F169I | STAD | 1 |
p.E441K | LUSC | 1 |
p.R390H | COAD | 1 |
p.R243X | STAD | 1 |
p.I110M | BLCA | 1 |
p.A170S | LUAD | 1 |
p.I335M | LUAD | 1 |
p.A247T | LUSC | 1 |
p.V323A | LIHC | 1 |
p.R84K | SKCM | 1 |
p.E417* | UCEC | 1 |
p.A273T | HNSC | 1 |
p.G144S | LUSC | 1 |
p.E297K | UCEC | 1 |
p.G106D | UCEC | 1 |
p.R243L | ESCA | 1 |
p.L425Q | KIRC | 1 |
p.G143S | UCEC | 1 |
p.R243* | STAD | 1 |
p.R229H | STAD | 1 |
p.W346L | UCEC | 1 |
p.V440M | COAD | 1 |
p.A333T | SKCM | 1 |
p.V182M | HNSC | 1 |
p.L157I | LIHC | 1 |
Top |
TissGeneCNV for TUBA3E |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for TUBA3E |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for TUBA3E |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for TUBA3E |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for TUBA3E |
TissGeneDrug for TUBA3E |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for TUBA3E |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |